IP Library Granted Patent US 11,713,471
Granted Patent B2
US 11,713,471 · App. 17/706,466 · Granted Aug 1, 2023

Class II, type V CRISPR systems

Inventors: Brian Thomas (Emeryville, CA); Christopher Brown (Emeryville, CA); Audra Devoto (Emeryville, CA); Cristina Butterfield (Emeryville, CA); Lisa Alexander (Emeryville, CA); Daniela S. A. Goltsman (Emeryville, CA); Justine Albers (Emeryville, CA); Alan Brooks (Emeryville, CA); Greg Cost (Emeryville, CA); Morayma Temoche-Diaz (Emeryville, CA); Cindy Castelle (Emeryville, CA); Rebecca Lamothe (Emeryville, CA)
Assignee: METAGENOMI, INC.
C12N15/90C12N9/22C12N15/1068C12N15/11C12N15/111C12N2310/20C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,713,471
App. No.
17/706,466
Granted
Aug 1, 2023
Kind
B2
Abstract

Described herein are methods, compositions, and systems derived from uncultivated microorganisms useful for gene editing.

Claims (28)

1. An engineered nuclease system comprising:

a. an endonuclease configured to be selective for a protospacer adjacent motif (PAM) sequence comprising the sequence 5′-YYn-3′ (SEQ ID NO: 3871), wherein said endonuclease is a class 2, type V Cas endonuclease, wherein said endonuclease comprises a WED II domain and a PAM-interacting domain having at least 80% amino acid sequence identity to the WED II domain and the PAM-interacting domain of the amino acid sequence of SEQ ID NO: 215; and

b. an engineered guide RNA, wherein said engineered guide RNA is configured to form a complex with said endonuclease and said engineered guide RNA comprises a spacer sequence configured to hybridize to a target nucleotide sequence.

2. The engineered nuclease system of claim 1 , wherein said WED II domain and PAM-interacting domain comprise an amino acid sequence having at least 90% amino acid sequence identity to amino acid residues 575-645 of the amino acid sequence of SEQ ID NO: 215.

3. The engineered nuclease system of claim 1 , wherein said engineered guide RNA comprises a nucleotide sequence with at least 80% nucleotide sequence identity to the non-degenerate nucleotides of the nucleotide sequence of SEQ ID NO: 3609.

4. The engineered nuclease system of claim 1 , wherein said endonuclease comprises a RuvC domain comprising an amino acid sequence having at least 80% amino acid sequence identity to the RuvCI, RuvCII and RuvCIII domains of the amino acid sequence of SEQ ID NO: 215, and wherein said endonuclease comprises the catalytic residues D886, E976, and D1129 of the amino acid sequence of SEQ ID NO: 215.

5. The engineered nuclease system of claim 1 , wherein said endonuclease comprises an amino acid sequence having at least 80% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 215, wherein said endonuclease comprises the catalytic residues D886, E976, and D1129 of the amino acid sequence of SEQ ID NO: 215.

6. The engineered nuclease system of claim 1 , wherein said engineered guide RNA comprises a sequence complementary to a eukaryotic, fungal, plant, mammalian, or human genomic polynucleotide sequence.

7. The engineered nuclease system of claim 1 , wherein said engineered guide RNA is 30-250 nucleotides in length.

8. The engineered nuclease system of claim 1 , wherein said endonuclease comprises one or more nuclear localization sequences (NLSs) proximal to an N- or C-terminus of said endonuclease.

9. The engineered nuclease system of claim 1 , wherein said endonuclease further comprises at least one of the following mutations: S168R, E172R, N577R, or Y170R when an amino acid sequence of said endonuclease is optimally aligned based on a pairwise alignment to the amino acid sequence of SEQ ID NO: 215.

10. The engineered nuclease system of claim 1 , wherein said endonuclease further comprises the mutations S168R and E172R when an amino acid sequence of said endonuclease is optimally aligned based on a pairwise alignment to the amino acid sequence of SEQ ID NO: 215.

11. The engineered nuclease system of claim 1 , wherein said endonuclease further comprises the mutations N577R or Y170R when an amino acid sequence of said endonuclease is optimally aligned based on a pairwise alignment to the amino acid sequence of SEQ ID NO: 215.

12. The engineered nuclease system of claim 1 , wherein said endonuclease further comprises the mutation S168R when an amino acid sequence of said endonuclease is optimally aligned based on a pairwise alignment to the amino acid sequence of SEQ ID NO: 215.

13. The engineered nuclease system of claim 12 , wherein said endonuclease does not comprise a mutation of E172, N577, or Y170 of the amino acid sequence of SEQ ID NO: 215.

14. The engineered nuclease system of claim 1 , further comprising a single- or double-stranded DNA repair template comprising from 5′ to 3′: a first homology arm comprising a sequence of at least 20 nucleotides 5′ to said target nucleotide sequence, a synthetic DNA sequence of at least 10 nucleotides, and a second homology arm comprising a sequence of at least 20 nucleotides 3′ to said target nucleotide sequence.

15. The engineered nuclease system of claim 14 , wherein said first or second homology arm comprises a nucleotide sequence of at least 40 nucleotides.

16. The engineered nuclease system of claim 14 , wherein said first and second homology arms are homologous to a genomic sequence of a eukaryote.

17. The engineered nuclease system of claim 14 , wherein said single- or double-stranded DNA repair template comprises a transgene donor.

18. The engineered nuclease system of claim 1 , further comprising a DNA repair template comprising a double-stranded DNA segment flanked by one or two single-stranded DNA segments.

19. The engineered nuclease system of claim 18 , wherein said single-stranded DNA segments are conjugated to the 5′ ends of said double-stranded DNA segment.

20. The engineered nuclease system of claim 18 , wherein said single-stranded DNA segments are conjugated to the 3′ ends of said double-stranded DNA segment.

21. The engineered nuclease system of claim 18 , wherein said single-stranded DNA segments have a nucleotide length from 4 to 10 nucleotide bases.

22. The engineered nuclease system of claim 18 , wherein said single-stranded DNA segments have a nucleotide sequence complementary to a nucleotide sequence within said spacer sequence.

23. The engineered nuclease system of claim 18 , wherein said double-stranded DNA sequence comprises a barcode, an open reading frame, an enhancer, a promoter, a protein-coding sequence, a miRNA coding sequence, an RNA coding sequence, or a transgene.

24. The engineered nuclease system of claim 18 , wherein said double-stranded DNA sequence is flanked by a nuclease cut site.

25. The engineered nuclease system of claim 1 , wherein said amino acid sequence identity is determined by a BLASTP, CLUSTALW, MUSCLE, MAFFT algorithm or a CLUSTALW algorithm with the Smith-Waterman homology search algorithm parameters.

26. The engineered nuclease system of claim 25 , wherein said amino acid sequence identity is determined by said BLASTP homology search algorithm using parameters of a wordlength (W) of 3, a expectation (E) of 10, and a BLOSUM62 scoring matrix setting gap costs at existence of 11, extension of 1 and using a conditional compositional score matrix adjustment.

Assignments (4)
CHANGE OF NAME Recorded Feb 6, 2026
From: METAGENOMI, INC.
To: METAGENOMI THERAPEUTICS, INC.
Reel/Frame 073717/0149 →
RELEASE OF SECURITY INTEREST Recorded Dec 12, 2025
From: CATALIO NEXUS FUND III, LP
To: AFFINI-T THERAPEUTICS, INC.
Reel/Frame 073201/0168 →
SECURITY INTEREST Recorded Mar 4, 2025
From: AFFINI-T THERAPEUTICS, INC.
To: CATALIO NEXUS FUND III, LP
Reel/Frame 070403/0862 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2022
From: THOMAS, BRIAN C.; BROWN, CHRISTOPHER; DEVOTO, AUDRA; BUTTERFIELD, CRISTINA; ALEXANDER, LISA; GOLTSMAN, DANIELA S.A.; ALBERS, JUSTINE B.; BROOKS, ALAN; COST, GREG; TEMOCHE-DIAZ, MORAYMA; CASTELLE, CINDY; LAMOTHE, REBECCA
To: METAGENOMI, INC.
Reel/Frame 060822/0177 →
Continuity (8)
Continuation PCTUS2021021259 · Mar 6, 2021
Provisional Application 63116157 · Nov 19, 2020
Provisional Application 63069699 · Aug 24, 2020
Provisional Application 63068316 · Aug 20, 2020
Provisional Application 63045815 · Jun 29, 2020
Provisional Application 63022276 · May 8, 2020
Provisional Application 62986477 · Mar 6, 2020
Related Publication 20220290187A1 · Sep 15, 2022
Cited By (1)
US 12,533,424